Pharmacogenomics and Theranostics in Practice: A summary of the Euromedlab-ESPT (The European Society of Pharmacogenomics and Theranostics) satellite symposium, May 2013.
作者信息
Siest Gérard, Schallmeiner Edith
机构信息
University of Lorraine , UMR INSERM U.1122 "IGE-PCV" Nancy, France.
Roche Diagnostics International Ltd , Rotkreuz, Switzerland.
出版信息
EJIFCC. 2013 Feb 21;24(3):85-9. eCollection 2013 Feb.
Abstract
摘要
相似文献
1
Pharmacogenomics and Theranostics in Practice: A summary of the Euromedlab-ESPT (The European Society of Pharmacogenomics and Theranostics) satellite symposium, May 2013.
EJIFCC. 2013 Feb 21;24(3):85-9. eCollection 2013 Feb.
2
Report from the European Society of Pharmacogenomics and Theranostics (ESPT) Inaugural Symposium 2011 in Bled.
Drug Metabol Drug Interact. 2012;27(1):55-6. doi: 10.1515/dmdi-2012-0004.
3
Conference scene: pharmacogenomics: from cell to clinic (part 2).
Pharmacogenomics. 2014 Apr;15(6):739-44. doi: 10.2217/pgs.14.36.
4
Pharmacogenomics: from cell to clinic (Part 1).
Pharmacogenomics. 2014 Apr;15(5):593-9. doi: 10.2217/pgs.14.35.
5
Need for pharmacogenomic information also for generic medications: recommendation of the European Society of Pharmacogenomics and Theranostics (ESPT).
Drug Metabol Drug Interact. 2012;27(2):119. doi: 10.1515/dmdi-2012-0010.
6
4th ESPT Conference: pharmacogenomics and personalized medicine - research progress and clinical implementation.
Pharmacogenomics. 2019 Oct;20(15):1063-1069. doi: 10.2217/pgs-2019-0095.
7
Pharmacogenetics in Latin American populations: regulatory aspects, application to herbal medicine, cardiovascular and psychiatric disorders.
Drug Metabol Drug Interact. 2012;27(1):57-60. doi: 10.1515/dmdi-2012-0006.
8
Systems medicine, personalized health and therapy.
Pharmacogenomics. 2015;16(14):1527-39. doi: 10.2217/pgs.15.103. Epub 2015 Sep 24.
9
Drug metabolism and drug interactions and the European Society of Pharmacogenomics and Theranostics.
Drug Metabol Drug Interact. 2012;27(2):61. doi: 10.1515/dmdi-2012-0009.
10
Ageing populations, complex diseases and their challenge to 21st century healthcare: the focus of the European Society for Pharmacogenomics and Theranostics.
Drug Metabol Drug Interact. 2011;26(2):43-4. doi: 10.1515/DMDI.2011.009.
本文引用的文献
1
High residual platelet reactivity on clopidogrel: its significance and therapeutic challenges overcoming clopidogrel resistance.
Cardiovasc Diagn Ther. 2013 Mar;3(1):23-37. doi: 10.3978/j.issn.2223-3652.2013.02.06.
2
Pharmacogenetic-guided dosing of coumarin anticoagulants: algorithms for warfarin, acenocoumarol and phenprocoumon.
Br J Clin Pharmacol. 2014 Apr;77(4):626-41. doi: 10.1111/bcp.12220.
3
Pharmacogenomics: from cell to clinic.
Drug Metabol Drug Interact. 2013;28(3):133. doi: 10.1515/dmdi-2013-0035.
4
Genetic determinants of dabigatran plasma levels and their relation to bleeding.
Circulation. 2013 Apr 2;127(13):1404-12. doi: 10.1161/CIRCULATIONAHA.112.001233. Epub 2013 Mar 6.
5
Pharmacogenomics in clinical practice and drug development.
Nat Biotechnol. 2012 Nov;30(11):1117-24. doi: 10.1038/nbt.2424. Epub 2012 Nov 8.
6
The role of therapeutic drug monitoring of imatinib in patients with chronic myeloid leukemia and metastatic or unresectable gastrointestinal stromal tumors.
Ther Drug Monit. 2012 Feb;34(1):85-97. doi: 10.1097/FTD.0b013e31823cdec9.
7
Use of amino-terminal pro-B-type natriuretic peptide to guide outpatient therapy of patients with chronic left ventricular systolic dysfunction.
J Am Coll Cardiol. 2011 Oct 25;58(18):1881-9. doi: 10.1016/j.jacc.2011.03.072.
8
Lebrikizumab treatment in adults with asthma.
N Engl J Med. 2011 Sep 22;365(12):1088-98. doi: 10.1056/NEJMoa1106469. Epub 2011 Aug 3.
9
How delayed graft function impacts exposure to mycophenolic acid in patients after renal transplantation.
Ther Drug Monit. 2011 Apr;33(2):155-64. doi: 10.1097/FTD.0b013e31820c0a96.
10
Translational research in oncology: key bottlenecks and new paradigms.
Expert Rev Mol Med. 2010 Oct 7;12:e32. doi: 10.1017/S1462399410001638.
Zotero 插件